Chiu Ying-Ming, Lan Joung-Liang, Huang Wei-Lieh, Wu Chi-Shin
Department of Allergy, Immunology, and Rheumatology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Front Med (Lausanne). 2023 Nov 2;10:1221393. doi: 10.3389/fmed.2023.1221393. eCollection 2023.
This study aimed to estimate the lifetime healthcare costs and loss of life expectancy (loss-of-LE) among patients with incident rheumatoid arthritis (RA) with and without depression.
This 18 years longitudinal cohort study used data from Taiwan's National Health Insurance Research Database. In total, 43,311 patients with RA were included. Among them, 1,663 patients had depressive disorders in the year preceding the RA diagnosis. The survival function for patients with RA with or without depression was estimated and extrapolated over a lifetime using the rolling extrapolation algorithm. The loss-of-LE was calculated by comparing the sex, age, and calendar year-matched referents from vital statistics. The average monthly cost was calculated as the sum of the monthly costs for all patients divided by the number of surviving patients. Lifetime healthcare costs were estimated by multiplying the monthly average cost by the monthly survival probability.
The loss-of-LE for RA patients with and without depression was 5.60 years and 4.76 years, respectively. The lifetime costs of RA patients with and without depression were USD$ 90,346 and USD$ 92,239, respectively. However, the annual healthcare costs were USD$ 4,123 for RA patients with depression and USD$ 3,812 for RA patients without depression. Regardless of sex or age, RA patients with depression had higher annual healthcare costs than those without depression.
Patients with RA and depression have a high loss-of-LE and high annual healthcare costs. Whether treating depression prolongs life expectancy and reduces healthcare costs warrants further investigation.
本研究旨在估计新发类风湿性关节炎(RA)伴或不伴抑郁症患者的终生医疗费用和预期寿命损失(LE损失)。
这项为期18年的纵向队列研究使用了台湾国民健康保险研究数据库的数据。总共纳入了43311例RA患者。其中,1663例患者在RA诊断前一年患有抑郁症。使用滚动外推算法估计并外推RA伴或不伴抑郁症患者的生存函数至终生。通过比较生命统计中性别、年龄和日历年份匹配的对照来计算LE损失。平均每月费用计算为所有患者每月费用总和除以存活患者数量。终生医疗费用通过将每月平均费用乘以每月生存概率来估计。
伴和不伴抑郁症的RA患者的LE损失分别为5.60年和4.76年。伴和不伴抑郁症的RA患者的终生费用分别为90346美元和92239美元。然而,伴抑郁症的RA患者的年度医疗费用为4123美元,不伴抑郁症的RA患者为3812美元。无论性别或年龄,伴抑郁症的RA患者的年度医疗费用均高于不伴抑郁症的患者。
RA伴抑郁症患者的LE损失高且年度医疗费用高。治疗抑郁症是否能延长预期寿命并降低医疗费用值得进一步研究。